02493.HK
Mabwell-b
HKSE · Healthcare · Biotechnology · CN
HKD 20.76
−0.38%Margins
Gross margin
81.6%
EBITDA margin
-100.5%
EBIT margin
-118.3%
Net margin
-123.4%
FCF margin
-63.7%
-860.9%
Return on equity
-20.1%
Return on assets
-29.4%
Return on invested capital
0.16x
Asset turnover
-HKD 357.9M
Cash from operations
—
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026